ATOSSA THERAPEUTICS, INC. Cost of Revenue
ATOSSA THERAPEUTICS, INC. (ATOS) reported Cost of Revenue of $0 for the 3-month period ending 2016-06-30, per its 10-Q filed 2016-08-12.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2017-03-21
- ATOSSA THERAPEUTICS, INC. cost of revenue for the quarter ending 2016-06-30 was $0.00.
- ATOSSA THERAPEUTICS, INC. cost of revenue for the quarter ending 2016-03-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. cost of revenue for the quarter ending 2015-12-31 was -$3.24M.
- ATOSSA THERAPEUTICS, INC. cost of revenue for the quarter ending 2015-09-30 was $313.41K.
- ATOSSA THERAPEUTICS, INC. cost of revenue for fiscal 2015 was $132.41K.
- ATOSSA THERAPEUTICS, INC. cost of revenue for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- ATOSSA THERAPEUTICS, INC. cost of revenue for fiscal 2013 was $345.52K, a 866.62% increase from fiscal 2012.
- ATOSSA THERAPEUTICS, INC. cost of revenue for fiscal 2012 was $35.74K, a 592.20% increase from fiscal 2011.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed | Cost of Revenue 41 month | Cost of Revenue 44 month | Cost of Revenue 47 month | Cost of Revenue 50 month | Cost of Revenue 53 month | Cost of Revenue 56 month | Cost of Revenue 59 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-06-30 | $0.00 10-Q · filed 2016-08-12 | $0.00 10-Q · filed 2016-08-12 | -$3.24M derived: sum of 3 quarters · filed 2017-03-21 | -$2.93M derived: sum of 4 quarters · filed 2017-03-21 | ||||||||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-05 | -$3.24M derived: sum of 2 quarters · filed 2017-03-21 | -$2.93M derived: sum of 3 quarters · filed 2017-03-21 | -$2.93M derived: sum of 4 quarters · filed 2017-03-21 | ||||||||||
| 2015-12-31 | -$3.24M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-03-21 | -$2.93M derived: sum of 2 quarters · filed 2017-03-21 | -$2.93M derived: sum of 3 quarters · filed 2017-03-21 | $132.41K 10-K/A · filed 2017-03-21 | ||||||||||
| 2015-09-30 | $313.41K 10-Q · filed 2015-11-12 | $313.41K derived: sum of 2 quarters · filed 2016-08-12 | $3.38M 10-Q · filed 2015-11-12 | $313.41K derived: sum of 4 quarters · filed 2016-08-12 | ||||||||||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-12 | $1.85M 10-Q · filed 2015-08-06 | $0.00 10-Q · filed 2016-08-12 | $3.06M 10-Q · filed 2015-08-06 | $0.00 derived: sum of 3 quarters · filed 2016-08-12 | $0.00 derived: sum of 4 quarters · filed 2016-08-12 | ||||||||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-05 | $1.21M 10-Q · filed 2015-05-13 | $0.00 derived: sum of 2 quarters · filed 2016-05-05 | $0.00 derived: sum of 3 quarters · filed 2016-05-05 | $0.00 derived: sum of 4 quarters · filed 2016-05-05 | |||||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $0.00 derived: sum of 3 quarters · filed 2016-03-30 | $0.00 10-K · filed 2016-03-30 | $340.66K 10-K · filed 2015-03-30 | |||||||||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-12 | $0.00 derived: sum of 2 quarters · filed 2015-11-12 | $0.00 10-Q · filed 2015-11-12 | $30.96K derived: sum of 4 quarters · filed 2015-11-12 | ||||||||||
| 2014-06-30 | $0.00 10-Q · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | $30.96K derived: sum of 3 quarters · filed 2015-08-06 | $56.90K derived: sum of 4 quarters · filed 2015-08-06 | ||||||||||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-13 | $30.96K derived: sum of 2 quarters · filed 2015-05-13 | $56.90K derived: sum of 3 quarters · filed 2015-05-13 | $279.06K derived: sum of 4 quarters · filed 2015-05-13 | $386.43K 10-Q · filed 2014-05-14 | |||||||||
| 2013-12-31 | $30.96K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $56.90K derived: sum of 2 quarters · filed 2015-03-30 | $279.06K derived: sum of 3 quarters · filed 2015-03-30 | $345.52K 10-K · filed 2015-03-30 | $386.43K 10-K · filed 2014-03-27 | |||||||||
| 2013-09-30 | $25.94K 10-Q · filed 2014-11-12 | $248.10K derived: sum of 2 quarters · filed 2014-11-12 | $314.56K 10-Q · filed 2014-11-12 | $320.32K derived: sum of 4 quarters · filed 2014-11-12 | $355.47K 10-Q · filed 2013-11-12 | |||||||||
| 2013-06-30 | $222.16K 10-Q · filed 2014-08-12 | $288.62K 10-Q · filed 2014-08-12 | $294.38K derived: sum of 3 quarters · filed 2014-08-12 | $303.38K derived: sum of 4 quarters · filed 2014-08-12 | $329.53K 10-Q · filed 2013-08-14 | |||||||||
| 2013-03-31 | $66.46K 10-Q · filed 2014-05-14 | $72.22K derived: sum of 2 quarters · filed 2014-05-14 | $81.22K derived: sum of 3 quarters · filed 2014-05-14 | $99.01K derived: sum of 4 quarters · filed 2014-05-14 | $107.37K 10-Q · filed 2013-05-15 | |||||||||
| 2012-12-31 | $5.76K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | $14.76K derived: sum of 2 quarters · filed 2014-03-27 | $32.55K derived: sum of 3 quarters · filed 2014-03-27 | $35.74K 10-K · filed 2014-03-27 | $40.91K 10-K · filed 2013-03-28 | |||||||||
| 2012-09-30 | $9.00K 10-Q · filed 2013-11-12 | $26.79K derived: sum of 2 quarters · filed 2013-11-12 | $29.98K 10-Q · filed 2013-11-12 | $35.15K derived: sum of 4 quarters · filed 2013-11-12 | $35.15K 10-Q/A · filed 2013-01-22 | |||||||||
| 2012-06-30 | $17.79K 10-Q · filed 2013-08-14 | $20.98K 10-Q · filed 2013-08-14 | $26.15K derived: sum of 3 quarters · filed 2013-08-14 | $26.15K derived: sum of 4 quarters · filed 2013-08-14 | ||||||||||
| 2012-03-31 | $3.20K 10-Q · filed 2013-05-15 | $8.36K derived: sum of 2 quarters · filed 2013-05-15 | $8.36K derived: sum of 3 quarters · filed 2013-05-15 | |||||||||||
| 2011-12-31 | $5.16K derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-03-28 | $5.16K derived: sum of 2 quarters · filed 2013-03-28 | $5.16K 10-K · filed 2013-03-28 | |||||||||||
| 2011-09-30 | $0.00 10-Q/A · filed 2013-01-22 | $0.00 10-Q/A · filed 2013-01-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |